Table 1.
Descriptive Statistics for PSADT < 12 Months Cohort, Stratified by Site
| Variable | All, n (%) | CPDR, n (%) | JHU, n (%) | P Value |
|---|---|---|---|---|
| N | 656 | 246 | 410 | |
| Age at RP, y | ||||
| Median (IQR) | 61.0 (56.0–65.1) | 62.9 (57.1–67.1) | 60.0 (55.0–64.0) | <.001 |
| Follow-up from RP, y | ||||
| Median (IQR) | 8.0 (4.9–13.0) | 8.5 (5.4–12.9) | 8.0 (4.0–13.0) | .098 |
| Race | ||||
| Caucasian | 544 (85.0) | 183 (77.2) | 361 (89.6) | |
| African American | 96 (15.0) | 54 (22.8) | 42 (10.4) | <.001 |
| Pathologic T stage | ||||
| T2 | 179 (27.6) | 104 (43.0) | 75 (18.5) | |
| T3–4 | 469 (72.4) | 138 (57.0) | 331 (81.5) | <.001 |
| Gleason sum | ||||
| ≤6 | 153 (23.5) | 98 (40.3) | 55 (13.4) | |
| 7 | 320 (49.1) | 102 (42.0) | 218 (53.0) | |
| 8–10 | 179 (27.4) | 43 (17.7) | 136 (33.2) | <.001 |
| Surgical margin | ||||
| Negative | 394 (61.4) | 119 (50.2) | 275 (67.9) | |
| Positive | 248 (38.6) | 118 (49.8) | 130 (32.1) | <.001 |
| PSADT, mos | ||||
| 10.51–11.99 | 80 (12.0) | 31 (12.6) | 49 (12.0) | |
| 9.01–10.50 | 86 (13.1) | 42 (17.1) | 44 (10.7) | |
| 7.51–9.00 | 80 (12.0) | 39 (15.8) | 41 (10.0) | |
| 6.01–7.50 | 93 (14.2) | 38 (15.4) | 55 (13.4) | |
| 4.51–6.00 | 99 (15.1) | 31 (12.6) | 68 (16.6) | |
| 3.01–4.50 | 97 (14.8) | 25 (10.2) | 72 (17.6) | |
| ≤3 | 121 (18.4) | 40 (16.3) | 81 (19.8) | .006 |
| Metastasis | ||||
| No | 406 (61.9) | 194 (78.9) | 212 (51.7) | |
| Yes | 250 (38.1) | 52 (21.1) | 198 (48.3) |
Abbreviations: CPDR = Center for Prostate Disease Research; IQR = interquartile range; JHU = Johns Hopkins University; PSADT = PSA doubling time; RP = radical prostatectomy.